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Abstract
There is a need for biomarkers to detect early joint inflammation and destruction of carti-
lage in different types of arthritis. YKL‐40, a 39 kDa heparin‐ and chitin‐binding secreted 
glycoprotein (also known as human cartilage gp39), has been recently discovered. Its 
exact biological function is still unclear. Specific receptors for YKL‐40 have not been iden-
tified yet. The clinical significance of YKL‐40 as a biomarker is discussed in different 
aspects. High level of YKL‐40 is found in various human i`nflammatory and neoplastic 
diseases. We present a review highlighting the information available on YKL‐40 and its 
significance in inflammatory joint diseases, like rheumatoid arthritis (RA). We also report 
original personal data on the topic concerning YKL‐40 levels in serum and synovial fluid 
of patients with RA in comparison with ultrasonographic parameters and cytokine lev-
els. The findings suggest that YKL‐40 might be implicated in the pathogenesis of the 
disease and could indicate the level of joint inflammation.
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1. Introduction
Identification of new biomarkers would be beneficial for improving biomedical research and 
drug development. Understanding the relationship between biological processes and clinical 
outcomes is significant for choosing optimal therapy [1].
A “biomarker” is “a characteristic that is objectively measured and evaluated as an indica-
tor of normal biological processes, pathogenic processes, or pharmacological responses to a 
therapeutic intervention” [2]. The acceptance of novel biomarkers in clinical settings requires 
detailed validation process before they could be used in routine clinical practice.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Utility of new biomarkers depends on several aspects: whether the method for detection of 
the biomarker is a specific, sensitive, fast, and affordable, if the level of the biomarker pro-
vides new information about the disease, if the concentration of the biomarker could help the 
patient's treatment [3].
The current review summarizes our investigations and presents evidences for the role of 
YKL‐40 in the diagnosis and prognosis monitoring of rheumatoid arthritis (RA).
2. YKL‐40: gene, protein, regulation, and proposed functions
2.1. YKL‐40: protein and gene
YKL‐40 is a glycoprotein that is encoded by the CHI3L1 gene and belongs to the mammalian 
chitinase‐like proteins [4].
Chitinases are enzymes that digest chitin, providing cellular and tissue remodeling during 
homeostasis in fungi, helminths, insects, and crustaceans [5]. Mammals express both enzy-
matically active chitinases and enzymatically inactive chitinase‐like proteins. The exact bio-
logic role of chitinase‐like proteins, such as human YKL‐40 protein, is still unclear.
YKL‐40 was found out in 1989 as the most abundant protein secreted by MG63 human osteo-
sarcoma cell line [6]. It is also known as human cartilage glycoprotein‐39 [4], chitinase 3‐like‐1 
protein [7], chondrex [8], and breast regression protein 39 kDa [9].
The human YKL‐40 gene is located on chromosome 1q32.1 and consists of 10 exons [7]. The 
promoter sequence contains binding sites for several known factors. The Sp1‐family tran-
scription factor had a dominant role in controlling YKL‐40 promoter activity [10]. It contains 
a single polypeptide chain, comprising 383 amino acids, where the three N‐terminal amino 
acids are Y (tyrosine), K (lysine), and L (leucine) and had a molecular mass of 40 kDa [4]. Two 
mutations of the catalytic glutamic and aspartic acids to leucine and to alanine, respectively, 
are responsible for the lack of hydrolase activity of YKL‐40 [10]. The crystallographic struc-
ture of human YKL‐40 exhibits two globular domains, forming a groove which corresponds 
to the active cite of the protein [10].
2.2. YKL‐40 ligands
Recent studies suggested different ligands for YKL‐40. It was determined that the glyco-
protein could facilitate the cross‐link between syndecan‐1 and integrin [11]. Syndecan‐1 is 
a heparan sulfate proteoglycan acting as a transmembrane receptor. Its coupling with other 
receptors such as integrins might induce cell adhesion and angiogenesis [12]. It was suggested 
that YKL‐40 could activate key signaling cascades—PI3K/AKT and MAPK/ERK resulting in 
high rate of cell proliferation and tumor cell survival [13, 14].
These signaling pathways could promote proliferation of synoviocytes and altered innate 
immunity in inflammatory arthritis [15, 16]. Kjaergaard et al. [17] suggested that another hepa-
ran sulfate proteoglycan, perlecan, might be a possible ligand for YKL‐40. It was revealed that 
perlecan comprised distinct effects on angiogenesis dependent on integrin coupling [17, 18].
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It was shown that lectin‐glycan associations determined the organization of plasma mem-
brane and modulated interactions between surface glycoproteins and receptors [19]. Recently, 
He et al. [20] identified the interleukin‐13 subunit α2 (IL‐13Raα2) as a possible receptor for 
YKL‐40. They found that the activation of YKL‐40 was not dependent on interaction with 
IL‐13Raα2, suggesting that a coreceptor should be considered. The authors supposed that 
IL‐13, IL‐13Raα2, and Chi3l1/YKL‐40/formed a multimeric complex, but they did not provide 
details [20].
Still unanswered questions are as follows: how YKL‐40 interacts with perlecan? how IL‐13, 
YKL‐40, and IL‐13Rα2 cooperate? whether the glycoprotein binds to other receptors?
2.3. YKL‐40 regulation
Studies focused on YKL‐40 regulation revealed controversial data and diverse effects.
Insulin growth factor‐I (IGF‐I) and insulin growth factor‐II (IGF‐II) were shown to trigger 
YKL‐40 secretion in guinea pig chondrocytes but not in human chondrocytes [21, 22]. The 
results might be due to differences in the investigated species.
Proinflammatory interleukins, such as IL‐2, IL‐6, IL‐12, IL‐13, IL‐17, and IL‐18, did not induce 
YKL‐40 transcription in astrocytes [23], while IL‐6 and IL‐17 showed enhanced production in 
human primary chondrocyte culture [22, 24].
Different kinds of stressors (hypoxia, ionizating radiation, treatment with TNF‐α, bFGF, p53 
inhibition, serum depletion) were shown to influence YKL‐40 induction on three human 
malignant glioma cell lines:U87, U118, and U373 [25]. It was found that corticosteroids inhib-
ited YKL‐40 protein and mRNA levels in subsets of macrophages (proinflammatory or classi-
cally activated macrophages) [26]. Zhang et al. determined that resveratrol inhibited YKL‐40 
expression by influencing its promoter activity and mRNA transcription levels in U87 cells in 
vitro [27].
Alterations in the extracellular microenvironment also alter YKL‐40 synthesis. Microarray 
gene expression analysis showed that the gene was overexpressed in dedifferentiated human 
fetal chondrocytes in comparison with differentiated chondrocytes [28].
YKL‐40 secretion is activated by cartilage resection or by replacement of chondrocytes from 
their native environment. The level of YKL‐40 secreted by normal cartilage explants is low 
during the first day of culture and increases significantly after a few days [22].
A study on the expression of YKL‐40 in normal mouse mammary gland development found 
that YKL‐40 was upregulated in ductal epithelial cells. The glycoprotein had the ability to 
inhibit epithelial secretion and differentiation and to facilitate cell migration under hormone 
stimulation [29].
The available data regarding the regulation of YKL‐40 are quite controversial. These results 
emphasize the differences in in vitro and in vivo effects of YKL‐40 on cellular and systemic 
response. We could suggest that YKL‐40 might play various roles depending on the cell type 
it is expressed by.
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2.4. Proposed functions for YKL‐40
Little is known about the functions of YKL‐40 in normal conditions. The glycoprotein is 
detected during early human embryonic development which is related to rapid proliferation 
and morphogenetic changes [30].
There is no fixed reference value for YKL‐40 in healthy people. It was determined that the 
level of the glycoprotein increased with age, and it was assumed to be used with an age‐
matched control group [31]. Johansen proposed serum YKL‐40 concentration higher than 20% 
to be considered as elevated [32]. Published levels of YKL‐40 in healthy individuals differ 
among populations [33–35] and are shown in Table 1. We could speculate that divergent 
YKL‐40 levels could be explained with differences in sample collection and assays, genetic 
polymorphisms, or even epigenetics.
Researchers suggest that YKL‐40 protects the extracellular matrix during tissue remodeling 
via suppression of different types of metalloproteinases [40]. Another study showed that the 
glycoprotein defined which cells to survive during mammary involution [41] and provided 
protection against apoptosis [42].
YKL‐40 was supposed to induce signaling cascades in connective tissue and functioned as 
a growth factor for synovial cells and chondrocytes [32]. It was found that YKL‐40 worked 
synergistically with insulin growth factor‐1 (IGF‐1) to induce fibroblasts growth [21]. YKL‐40 
was discussed as a differentiation marker for monocytes [7], mesenchymal stem cells [43], and 
chondrocytes [44].
YKL‐40 functions as a migration and adhesion factor for vascular cells and helps the forma-
tion of branching tubules. Thus, the glycoprotein could play a role in angiogenesis [11].
A variety of independent investigations demonstrated that high levels of YKL‐40 were 
related to metastasis and poor survival in different human carcinomas, such as breast  cancer 
[11], colorectal cancer [45], ovarian cancer [46], high‐grade glioma [47], and lymphoma [48], 
s uggesting that YKL‐40 might serve as a diagnostic, risk assessment, and prognostic bio-
marker. Other studies indicated that YKL‐40 increased also in inflammatory disorders associ-
ated with tissue remodeling and destruction [24, 49].
Population Serum YKL‐40 levels References
1. Danish 43 [33]
2. French 59 [36]
3. Chinese 61.1 [37]
4. Bulgarian 84.19 [35]
5. Japanese 101.7 [38]
6. Turkish 114 [34]
Table 1. Mean serum YKL‐40 levels (ng/ml) in healthy individuals from different populations [39].
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YKL‐40 is a member of an evolutionary highly conserved protein family, described not only 
in humans [9, 30], proposing important biological role in normal and pathological conditions. 
The summarized functions of YKL‐40 are presented in Figure 1.
3. YKL‐40 and rheumatoid arthritis
It is believed that genetic and environmental factors are implicated in the etiology of RA. It is 
a chronic inflammatory disease which affects about 0.5–1% of the population. Patients suffer 
from chronic synovial inflammation, joint degradation, and functional disability [50]. Even 
though some clinical laboratory parameters are related to the risk of radiographic progres-
sion, they do not illustrate individual features in the pathogenesis of disease [51].
There is a lack of specific markers for early diagnosis, prognosis, and monitoring of effective 
treatment. Reliable biomarkers of joint inflammation and destruction in RA should be pro-
teins produced by cells in the synovial fluid and leading to pathological alterations. YKL‐40 
is expressed and secreted by activated macrophages and neutrophils, fibroblast‐like synovial 
cells, chondrocytes, and vascular smooth muscle cells [32]. Our immunocytochemical study 
also found that YKL‐40 was present in polymorphonuclear cells in the synovial fluid of RA 
patients [52]. We suppose that it might reflect more precisely the local inflammatory process.
Figure 1. Biological functions of YKL‐40. Involvement in cell growth and differentiation, cell survival, inflammatory 
disorders and tumor development; participation in two basic cell signaling cascades.
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The investigations on the significance of serum YKL‐40 as a novel inflammatory biomarker are 
polar. Some researchers show that it could be useful as an informative parameter in disease diag-
nosis and monitoring [53], and others state that it is merely a marker of joint inflammation [54].
3.1. YKL‐40 in serum and synovial fluid
Johansen detected a 10‐fold increase in the concentration of YKL‐40 in synovial fluid com-
pared to serum levels in RA patients and proposed that the level of YKL‐40 might reflect carti-
lage degradation and synovial inflammation in RA [32]. These findings are in agreement with 
other studies, suggesting that YKL‐40 is associated with the development of osteoarthritis and 
should be considered as a potential target for treatment [55].
Our observations focused on YKL‐40 in RA patients also found significantly higher glyco-
protein concentrations in the synovial fluid in comparison with serum levels [35]. However, 
we determined the same pattern of expression in other inflammatory joint diseases such as 
osteoarthritis, gout, and psoriatic arthritis [56].
Huber et al. established synovial antigen microarray technology to analyze antibody profile in 
RA patients. The synovial glycoprotein YKL‐40 was one of the 225 peptides and proteins stud-
ied, and it was proved to generate autoantibody production [57]. YKl‐40 was also detected as a 
target of T cells and as a specific and independent histologic marker in arthritic synovitis [58, 59].
There are a number of studies in which a multi‐biomarker disease activity (MBDA) score is 
used to evaluate disease activity, prediction of radiographic progression, and prognosis in RA 
patients. MBDA score is estimated by measuring the concentrations of 12 serum biomarkers. 
YKL‐40 is a part of the established panel of parameters [60, 61]. This fact confirms the poten-
tial significance of YKL‐40 in the pathogenic route of RA.
The role of YKL‐40 in inflammation still remains to be resolved. The question is whether 
YKL‐40 is an active participant in the process of inflammation or is a result of the body 
response to it.
3.2. YKL‐40 and conventional laboratory parameters
C‐reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are the best known and 
frequently used conventional parameters at the time of diagnosis of RA, but they are not con-
sidered as predictors of poor prognosis. Radiological progression of joint destruction could 
often appear despite normal values. This is a common event in early RA stages [62].
Several studies investigated the significance of YKL‐40 in relation to CRP and ESR [53]. We also 
determined a strong association between YKL‐40 levels in serum and synovial fluid and CRP 
and ESR [35]. Thus, YKL‐40 could be regarded as an informative proinflammatory biomarker.
3.3. YKL‐40 and ultrasonography
Angiogenesis is a major result of synovial inflammation and maintenance of the pannus in 
RA [63]. Conventional radiology and tomography could not provide direct visualization of 
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the joint cartilage. The decreased in joint space is only an indirect evidence for joint destruc-
tion. Some authors use ultrasonograhy to measure and register early arthritic changes in joint 
thickness and to figure joint surfaces before they could be detected by routine radiologic 
methods [64]. We also applied ultrasonography as a sensitive technique for detecting syno-
vial alteration. A relationship between ultrasonographic findings and YKL‐40 was detected. 
Analysis of the data confirmed that the sonographic inflammation correlated with angiogen-
esis of the synovial membrane [35].
3.4. YKL‐40 and angiogenesis
Vascular epidermal growth factor (VEGF) is a key factor in the pathogenesis of RA, serving 
both as a cell mitogen for endothelial cells and as a factor defining vascular permeability [65]. 
Several research groups revealed that secreted and expressed VEGF was related to the inflam-
matory response, to changes in the synovium, and to other conventional markers [65, 66].
YKL‐40 also promotes attachment and migration of vascular endothelial cells, which indi-
cates that the protein participates in angiogenesis [11]. Francescone et al. showed that YKL‐40 
induced VEGF expression in the U87 glioblastoma cell line and supposed that both molecules 
synergistically promoted endothelial cell angiogenesis [67].
VEGF was influenced by hypoxia, which contributed to RA development and altered response 
in arthritic synovium [64]. Similarly, YKL‐40 was also upregulated by hypoxia in tumor cells 
[25]. It is assumed that the pathogenic features of arthritic synovium share the same charac-
teristics with tumor cells.
3.5. YKL‐40 and cytokines
Recent studies defined proinflammatory cytokines as major participants in RA pathogenesis 
resulting in identification of new molecular targets. It was shown that the production of tumor 
necrosis factor‐alpha (TNF‐α) is involved in the pathogenesis of RA [68], and biological inhibi-
tors of this cytokine were approved for clinical use [69]. It was proved that levels of proinflam-
matory cytokines such as IL‐1α, TNF‐α, IL‐6, and IFN‐γ in the serum and synovial fluid of RA 
patients correlated with disease activity and progression [70]. Our investigations determined 
a strong link between serum and synovial levels of YKL‐40 and serum TNF‐α and IL‐1β in 
patients with RA [71]. The cellular sources of TNF‐α and IL‐1β are circulating monocytes and 
macrophages [72]. It was shown that YKL‐40 originated from the same cell types [32].
4. Conclusion
Investigations published so far determine YKL‐40 as an important molecule in RA patho-
genesis. It is assumed that circulating YKL‐40 might reflect precisely the activity of local and 
systemic inflammation. The clinical utility of YKL‐40 as diagnostic or prognostic marker in 
RA remains to be further clarified, but still it gives rise to serious expectations in the search of 
new promising biomarkers.
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